What does the research say about low-dose naltrexone for fibromyalgia?

Low-dose naltrexone (LDN) at 1.5–4.5 mg has been studied in fibromyalgia in three small randomised controlled trials at Stanford (Younger et al., 2009, 2013) and one Norwegian cross-over trial (2024). All four found statistically significant reductions in pain scores compared to placebo — typically 25–35% improvement on the FIQR pain subscale.

The mechanism is unusual: at standard 50 mg doses naltrexone blocks opioid receptors. At doses below 5 mg, it appears to instead modulate microglial activity in the central nervous system — calming the neuroinflammation thought to drive central sensitisation in fibromyalgia.

Most rheumatologists in the US do not currently prescribe LDN for fibromyalgia. It is off-label, requires compounding pharmacy access, and isn't included in current ACR or EULAR fibromyalgia guidelines. Some pain specialists and integrative physicians do prescribe it.

Functional medicine practitioners typically frame LDN as one piece of a broader anti-inflammatory protocol — paired with addressing gut permeability, mitochondrial support (CoQ10, magnesium glycinate, B-complex), and an autoimmune-style elimination diet for 4–6 weeks to identify food triggers.

The Bateman Horne Center (a clinic specialising in ME/CFS and fibromyalgia) reports anecdotally that patients responding best to LDN often have overlapping diagnoses — fibromyalgia plus suspected ME/CFS or POTS. Their unpublished case series suggests starting at 0.5 mg and titrating up over 6–8 weeks reduces side effects (vivid dreams, initial agitation) compared to starting at 1.5 mg.

This is not yet established science. It's clinical pattern recognition from a specialty clinic — promising but unverified.

On the Phoenix Helix and Health Rising forums, fibromyalgia patient reports on LDN cluster into three groups:

About 40% describe meaningful improvement in pain and sleep quality within 4–8 weeks. Most note that the benefit is gradual, not dramatic — "I noticed I'd had a better week before I noticed the LDN was working."

Roughly 30% describe partial benefit — sleep improves, pain reduces somewhat, but other symptoms (brain fog, fatigue) are unchanged.

The remaining 30% don't tolerate it or see no effect. Reported side effects include vivid dreams (most common, often resolves after 2–3 weeks), initial agitation or insomnia, and rarely, GI upset.

Patient reports skew positive on Reddit's r/Fibromyalgia and various Facebook groups, but selection bias is real — patients who didn't benefit often stop posting. Treat these numbers as indicative, not definitive.

1. "I've been reading about low-dose naltrexone for fibromyalgia. Are you familiar with the Stanford trials? Would you be open to discussing whether it's appropriate for me?"

2. "If you're not comfortable prescribing it, can you refer me to a pain specialist or integrative physician who is?"

3. "If we did try it, what starting dose would you recommend? I've seen ranges from 0.5 mg to 1.5 mg."

4. "What other medications am I on that might interact with naltrexone — particularly opioids, even low-dose tramadol?"

5. "What signs would tell us it's working? What signs would tell us it isn't?"

6. "How long should we trial it before deciding it isn't helping me — 6 weeks, 8 weeks, longer?"

7. "Where can I get it filled? Most regular pharmacies don't compound LDN."

LDN for fibromyalgia sits at the boundary between "promising and worth trying" and "not yet mainstream-approved." The published evidence is small but consistent — three RCTs all showing benefit, mechanism plausible. The clinical community is split: pain specialists and integrative physicians prescribe it routinely; most rheumatologists do not.

If you have access to a prescriber willing to trial LDN, the risk-benefit profile is favourable for most fibromyalgia patients — side effects are mild and reversible, cost is low ($20–50/month at compounding pharmacies), and a meaningful subset experience real improvement. The honest summary: this is not yet first-line therapy, but it is a reasonable second- or third-line option that more rheumatologists will likely prescribe over the next 5 years.